1 A phase I/II clinical trial of intradermal, controllable self-replicating RNA vaccine

2 EXG-5003 against SARS-CoV-2

- 3
- 4 Takenao Koseki,¹ Mayumi Teramachi,² Minako Koga³, Minoru S.H. Ko⁴, Tomokazu Amano⁴,
- 5 Hong Yu⁴, Misa Amano⁴, Erica Leyder⁴, Maria Badiola⁴, Priyanka Ray⁴, Jiyoung Kim⁴, Akihiro
- 6 C. Ko⁴, Achouak Achour⁵, Nan-ping Weng⁵, Takumi Imai⁶, Hisako Yoshida⁶, Satsuki Taniuchi⁶,
- 7 Ayumi Shintani⁶, Hidetsugu Fujigaki⁷, Masashi Kondo^{2,8}, Yohei Doi^{9,10,11}
- 8
- 9 1 Department of C Pharmacotherapeutics and Informatics, Fujita Health University School of
- 10 Medicine, Toyoake, Aichi, Japan
- 11 2 Center for Clinical Trial and Research Support, Fujita Health University School of Medicine,
- 12 Toyoake, Aichi, Japan
- 13 3 KM Pharmaceutical Consulting, Washington, D.C., USA
- 14 4 Elixirgen Therapeutics, Inc., Baltimore, MD, USA
- 15 5 Laboratory of Molecular Biology and Immunology, National Institute on Aging, National
- 16 Institutes of Health, Baltimore, MD, USA
- 17 6 Department of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan
- 18 University, Osaka, Japan
- 19 7 Department of Advanced Diagnostic System Development, Fujita Health University Graduate
- 20 School of Health Sciences, Toyoake, Aichi, Japan
- 21 8 Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake,
- 22 Aichi, Japan

23	9 Departments of Microbiology and Infectious Diseases, Fujita Health University School of
24	Medicine, Toyoake, Aichi, Japan
25	10 Center for Infectious Disease Research, Fujita Health University, Toyoake, Aichi, Japan
26	11 Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh,
27	Pennsylvania, USA
28	
29	Running head: Phase I/II trial of SARS-CoV-2 srRNA vaccine EXG-5003
30	
31	Keywords: COVID-19, messenger RNA, receptor-binding domain, safety, immunogenicity
32	
33	Correspondence:
34	Yohei Doi, MD, PhD, Departments of Microbiology and Infectious Diseases, Fujita Health
35	University School of Medicine, Toyoake, Aichi 470-1192 Japan. Phone: +81-562-93-2433, Fax:
36	+81-562-93-4003, Email: yoheidoi@fujita-hu.ac.jp.
37	
38	

39 Abstract

40	mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
41	played a key role in reducing morbidity and mortality from coronavirus disease 2019
42	(COVID-19). We conducted a double-blind, placebo-controlled phase I/II trial to evaluate the
43	safety, tolerability, and immunogenicity of EXG-5003, a two-dose, controllable self-replicating
44	RNA vaccine against SARS-CoV-2. EXG-5003 encodes the receptor binding domain (RBD) of
45	SARS-CoV-2 and was administered intradermally without lipid nanoparticles (LNP). The
46	participants were followed for 12 months. Forty healthy participants were enrolled in Cohort 1 (5
47	μ g per dose, n = 16; placebo, n = 4) and Cohort 2 (25 μ g per dose, n = 16; placebo, n = 4). No
48	safety concerns were observed with EXG-5003 administration. SARS-CoV-2 RBD antibody
49	titers and neutralizing antibody titers were not elevated in either cohort. Elicitation of antigen-
50	specific cellular immunity was observed in the EXG-5003 recipients in Cohort 2. At the 12-
51	month follow-up, participants who had received an approved mRNA vaccine (BNT162b2 or
52	mRNA-1273) >1 month after receiving the second dose of EXG-5003 showed higher cellular
53	responses compared to equivalently vaccinated participants in the placebo group. The findings
54	suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-
55	CoV-2 mRNA vaccines.

56

58 Introduction

Since its onset in late 2019, the COVID-19 pandemic has resulted in over 7 million deaths ¹ and 59 has left many more people with negative long-term health consequences worldwide. Against this 60 61 backdrop, the rapid development of multiple COVID-19 vaccines has been a significant achievement in the field of biomedical research, with billions of vaccine doses distributed and 62 administered worldwide². In particular, synthetic mRNA vaccines made a noteworthy debut 63 following extensive fundamental and preclinical investigations that preceded the pandemic ^{3,4}. 64 With their rapid development, cell-free manufacturing, and excellent clinical efficacy, mRNA 65 66 vaccines surpassed conventional live-attenuated, inactivated, and protein-based subunit vaccines 67 in the race for early vaccine approval. Nonetheless, mass administration of mRNA vaccines has also revealed challenges, including adverse effects and the need for multiple booster doses. 68 69 Another consideration in vaccine development is the role of vaccine-induced cellular immunity in protection against severe disease, hospitalization, and death. As SARS-CoV-2 variants that 70 71 evade neutralizing antibodies continue to emerge, the significance of cellular immunity, 72 especially CD8+ T cells, in safeguarding against severe disease in the long run is increasingly appreciated ⁵⁻⁷. In contrast to the limited cross-reactivity of neutralizing antibodies induced by 73 vaccines against variants, T cell responses elicited by vaccines demonstrate excellent cross-74 75 reactivity. However, the approved mRNA vaccines induce weak cellular immunity, especially in CD8+T cells ⁸⁻¹⁰, that wanes rapidly along with humoral immunity ^{11,12}, though some groups 76 report longer-lasting T cell immunity¹³⁻¹⁵. 77 The weak induction and rapid waning of cellular immunity of the currently approved mRNA 78

79 vaccines could be overcome by another type of mRNA vaccines using self-replicating RNA

80 (srRNA), also called self-amplifying RNA (saRNA or SAM-RNA)¹⁶, as it is known to be a

strong inducer of cellular immunity in animal studies ¹⁷⁻²³. However, clinical trials of the SARSCoV-2 vaccine based on the srRNA/saRNA platform thus far have shown lower than expected
immunogenicity in humans ²⁴⁻²⁶.

84 The EXG-5003 vaccine is based on srRNA/saRNA technology, but it is engineered to be controllable by temperature: it functions at around 33°C - skin temperature, but does not 85 function at 37°C – core body temperature ²⁷. Thus, this novel RNA vaccine platform is called 86 87 controllable self-replicating RNA (c-srRNA)²⁷. Unlike mRNA and srRNA/saRNA vaccines that are administered to skeletal muscles, the c-srRNA vaccine platform is optimized for intradermal 88 89 delivery, which may enhance cellular immunity as it is well known that intradermal vaccination can induce strong cellular immunity ^{28,29}. Also, unlike mRNA and srRNA/saRNA vaccines that 90 91 are complexed with LNP, the c-srRNA vaccine platform is not complexed with LNP and is 92 delivered as naked RNA, which may reduce local reactogenicity in the skin, which has often 93 been an issue for previous intradermal vaccines. Preclinical studies have shown that intradermal 94 vaccination with EXG-5003 alone induced robust cellular immunity but did not induce humoral 95 immunity²⁷. However, EXG-5003 showed priming effects, as demonstrated by a rapid and 96 strong induction of humoral immunity after subsequent exposure to the same or variant RBD antigen compared with control ²⁷. 97 Here, we report the results of a phase 1/2 study to evaluate the safety, tolerability, and 98

immunogenicity of EXG-5003 in healthy adults.

100

101 **Results**

102 **Participants**

103	Of 46 participants who gave consent, 40 participants met the inclusion criteria. They were
104	enrolled in Cohort 1 and Cohort 2 of this study, with 16 participants assigned to receive
105	EXG-5003 and 4 participants to receive placebo in each cohort, respectively (Figure 1).
106	In Cohort 1, one participant in the EXG-5003 5 μ g group did not receive the second dose due to
107	an unrelated injury requiring hospitalization. All 40 participants completed follow-up to Day 57.
108	One and 3 participants in Cohort 1 (EXG-5003 5 μg group) and Cohort 2 (EXG-5003 25 μg
109	group) did not return at the 1-year final follow-up, respectively.
110	The participant backgrounds for the full analysis set (FAS) in this study are shown in Table 1.
111	For Cohort 1, males accounted for 10/16 (62.5%) in the EXG-5003 5 μ g group and 3/4 (75%) in
112	the placebo group. The median age was 39.5 years in the EXG-5003 5 μ g group and 48 years in
113	the placebo group. For Cohort 2, males accounted for 7/16 (43.8%) in the EXG-5003 25 μg
114	group and 4/4 (100%). The median age was 43 years in the EXG-5003 25 μg group and 44 years
115	in the placebo group.
116	Safety
117	Local adverse events or reactogenicity associated with the administration of EXG-5003 are

summarized in Figure 2A. Only Grade 1 events were reported from a small number of 118 119 participants. A photo shows an example of observed redness (Figure 2A). Systemic adverse 120 events are summarized in Figure 2B. Only minor events, mostly Grade 1 and some Grade 2, 121 were reported. It is noteworthy that the reactogenicity and systemic adverse events associated with EXG-5003 were much lower than the approved mRNA vaccines ^{3,4} and other 122 123 srRNA/saRNA vaccines ^{26,30}. This low reactogenicity of the intradermal EXG-5003 vaccine was 124 expected because the vaccine contains only RNA and did not contain skin irritants such as lipids 125 or oils.

126 Short-term humoral immunity elicited by EXG-5003

127 The results of the FAS for anti-SARS-CoV-2 RBD antibody titers are shown in Figure 3, which 128 plots the geometric means of titer for each participant by dose group and by time of evaluation 129 over time (Table S1). Placebo groups consisting of 4 participants each from Cohort 1 and Cohort 130 2 were plotted together. As external controls, serum from four convalescent individuals who 131 were hospitalized for COVID-19 and one serum sample from the WHO COVID-19 reference 132 were analyzed in parallel (Table S2). Because the participants were allowed to receive licensed 133 COVID-19 vaccines after Day 57, humoral immunity elicited by EXG-5003 alone could be 134 assessed until Day 57. As shown in Figure 3, some individuals in the placebo group showed 135 antibody titers higher than those who were vaccinated at some time points. They were negative 136 for COVID-19 based on ELISA results against the nucleoprotein of SARS-CoV-2 and did not 137 receive licensed COVID-19 vaccines during this period; thus, the reason for these high titers was 138 not clear. For EXG-5003 vaccinated groups, low or undetectable levels of an anti-SARS-CoV-2 139 RBD antibody were observed (Figure 3A). Similarly, the results of the FAS for neutralizing 140 antibody (ntAb), by both cell-free SARS-CoV-2 neutralization assay (Figure 3B, Table S3) and 141 pseudotyped lentivirus assay (Figure 3C, Table S4), showed low or no increase of titers 142 compared to the placebo group. Data points shown in red indicate individuals who received at 143 least one dose of the approved mRNA vaccines (BNT162b2 or mRNA-1273) at the time of 144 serum collection. These data will be discussed later.

145 Short-term cellular immunity elicited by EXG-5003

The results of the FluoroSpot assay for IFN-γ and IL-4 are shown in Figure 4. Cellular immunity
was tested by stimulating PBMCs with a 15-mer peptide pool and a 9-mer peptide pool, which

148 cover the RBD antigen. Short-term cellular immunity (up to Day 57) did not seem to be induced

149	by EXG-5003 compared to the placebo and external controls, including convalescent individuals
150	and individuals vaccinated with the BNT162b2 mRNA vaccine (Figure 4). However, some
151	individuals in the placebo group and one individual in the external controls before BNT162b2
152	vaccination (BNT16b2 [pre]) showed cellular immunity comparable to the convalescent
153	individuals. Also, two of three individuals who received one dose of BNT162b2 vaccine
154	(BNT162b2 [1 dose]) and one of three individuals who received two doses of BNT162b2
155	vaccine (BNT162b2 [2 doses]) showed rather low cellular immunity, which is comparable to the
156	EXG-5003 vaccinated group. Measurements for Cohort 1 (16 EXG-5003 5 μ g and 4 placebo
157	participants) and Cohort 2 (16 EXG-5003 25 μ g and 4 placebo participants) were conducted in
158	different batches on separate periods. We reasoned that the assays performed at the same time
159	would demonstrate more consistent results. Therefore, we looked at Cohort 2 separately (Figure
160	5). This showed a clearer pattern of gradual increase of cellular immunity in the EXG-5003
161	group compared to the placebo group (Figure 5). Notably, some individuals who received
162	EXG-5003 25 μ g even after a single dose showed higher cellular immunity than two of three
163	individuals who received a single dose of BNT162b2 vaccine (BNT162b2 [1 dose]) and one of
164	three individuals who received two doses of BNT162b2 vaccine (BNT162b2 [2 doses]).
165	Long-term humoral immunity elicited by EXG-5003 following administration of licensed
166	vaccines
167	During this trial, approved SARS-CoV-2 vaccines became available in Japan. Therefore, the

participants were unblinded from randomization at Day 57 and allowed to receive the approved
SARS-CoV-2 vaccines (BNT162b2, mRNA-1273, ChAdOx1, NVX-CoV2373) during the rest of
the follow-up period. Some participants started to receive the approved vaccines. At the time of
the final 1-year follow-up, some participants took two or three doses of the approved vaccines

172	(BNT162b2 or mRNA-1273), whereas some participants did not take any approved vaccines.
173	Whether the participants took the approved vaccines or not rests on the participants' free-will.
174	Although the number of participants in these subgroups was very small, we expected that the
175	general trends without inference could be observed.
176	Although the data were not necessarily consistent among the assays (Ab titer, ntAb titer
177	[pseudovirus], ntAb titer [cell-free]), there were general tendencies that participants who
178	received EXG-5003 vaccines (both 5 μg and 25 μg groups) showed higher antibody levels than
179	participants who did not receive EXG-5003 (placebo group; PBO) (Figure 6). The timing of
180	blood sampling after the dosing of approved vaccines was not controlled, but there was no clear
181	pattern of timing differences among the three groups, i.e., PBO, EXG-5003 (5 μ g), EXG-5003
182	(25 µg).
183	Notably, at 3 months post EXG-5003 vaccination when participants received only a single dose
184	of BNT162b2 or mRNA-1273, participants who received prior EXG-5003 showed Ab titers
185	higher than participants who did not receive EXG-5003 (PBO) (Figure 6A). Especially, EXG-
186	5003 25 μ g group showed the Ab titer comparable to participants who received two doses of
187	BNT162b2 or mRNA-1273, but not received EXG-5003 (PBO) (Figure 6A). Similar trends were
188	observed for ntAb titers assessed by both cell-free assay (Figure 6B) and pseudovirus assay
189	(Figure 6C).
190	Taken together, EXG-5003 may have a priming effect for humoral immunity on subsequent
191	heterologous vaccine administration.
192	Long-term cellular immunity elicited by EXG-5003 following administration of licensed
193	vaccines

194 The priming effect of EXG-5003 on subsequent heterologous vaccine administration was more 195 clearly seen for cellular immunity. Figure 7A shows cellular immunity assayed by 15-mer 196 peptide stimulation (i.e., CD4+, CD8+ T cells) at the 1-year follow-up (Table S5). Among 197 participants who did not receive any approved vaccines by the 1-year follow-up, some 198 individuals who received EXG-5003 vaccines possessed higher cellular immunity compared to 199 the placebo group. These individuals were negative for SARS-CoV-2 nucleoprotein and, thus, 200 were not infected throughout the study period. This trend was observed for participants who received two or three doses of an approved vaccine. The timing of blood sampling after the last 201 202 vaccination (either EXG-5003 or approved vaccines) was around 10 months for no approved 203 vaccine group, around 8 months for two doses of approved vaccines group, and around 1 month 204 for three doses of the approved vaccines group (see the details in Figure 7 legend). The external 205 controls were reproduced from Figure 5 for the comparison. For the convalescent group, blood 206 sampling was done 20, 21, 21, and 22 days from the onset of COVID-19 symptoms. Blood 207 sampling of BNT162b2 vaccine groups occurred before vaccination (BNT162b2 [pre]), 2 weeks 208 after the first vaccination (BNT162b2 [1 dose]), and 2 weeks after the second vaccination 209 (BNT162b2 [2 doses]) (Table S6). Two weeks after the vaccination is considered the time for peak cellular immunity ^{11,12,25,26}. 210

Figure 7B shows cellular immunity assayed by 9-mer peptide stimulation (i.e., mainly CD8+ T
cells) at the 1-year follow-up. There were fewer 9-mer than 15-mer peptide results as we
prioritized the 15-mer peptide assays when blood samples were insufficient to run both.
However, the priming effect of EXG-5003 was even more clearly seen compared to 15-mer
peptide results (Figure 7A). Interestingly, both convalescent and twice BNT162b2 vaccinated
individuals (BNT162b2 [2 doses]) in the control group showed very low 9-mer peptide results.

This may be consistent with the notion that mRNA vaccine is a weak inducer of CD8+ T cells ⁸⁻
 ¹⁰. The result shown in Figure 7B further highlights the potential of the EXG-5003 vaccine to
 enhance the CD8+ T cell response.

220

221 Discussion

222 Synthetic mRNA vaccines have been enormously successful in combating the SARS-CoV-2

223 pandemic. However, it has also become clear that humoral immunity, and subsequently cellular

immunity, rapidly wane, and thus, repeated vaccinations are recommended ^{11,12}. Ideally, a

225 vaccine that can provide long-term immune protection is desirable. Also, a vaccine that can

provide not only humoral immunity, but strong cellular immunity, is desirable, because the

227 cellular immunity is known to be more protective against variant forms of the virus. We

attempted to address these issues with a novel intradermal c-srRNA vaccine platform, which is

229 different from all currently licensed SARS-CoV-2 vaccines or those under development. For

example, as far as we know, EXG-5003 is the only RNA vaccine that is administered

231 intradermally and without LNP. Most likely due to this feature, the vaccine showed an excellent

232 safety profile, including very few local and systemic adverse events.

233 As a standalone vaccine, the EXG-5003 vaccine did not induce Ab production. To some extent,

this was expected from mouse studies²⁷. On the other hand, mouse studies showed the induction

of strong cellular immunity in both CD4+ and CD8+ T cells²⁷, but the cellular immunity in

humans was rather weak with a dose of up to $25 \mu g$. However, it is worth noting that the level of

237 cellular immunity achieved by EXG-5003 was comparable to traditional srRNA/saRNA

vaccines, which are administered intramuscularly with LNP^{25,26}. Although the dose of traditional

srRNA/saRNA vaccines was limited to 10 µg due to local and systemic adverse events, including

grade 3 severity²⁶, EXG-5003 can be dosed up to 25 μ g without any severe adverse events. In 240 fact, the clinical trial originally considered dose escalation of up to 100 µg, but this was not 241 242 conducted due to insufficient induction of Ab production at 5 and 25 µg doses. Therefore, it 243 remains to be seen whether higher doses of EXG-5003 can induce more robust cellular immunity 244 as well as humoral immunity. 245 Surprisingly, EXG-5003 appears to provide long-term and enhanced priming effects on 246 heterologous synthetic mRNA vaccines. For example, for T cell responses, assessed by 247 FluoroSpot assays, in individuals who received EXG-5003 showed higher T cell immunity even 248 around 10 months after receiving the licensed mRNA vaccines (i.e., booster) compared to 249 individuals who did not receive EXG-5003. This priming effect was more pronounced in the 250 FluoroSpot assays using a 9-mer peptide pool than those using a 15-mer peptide pool. Assuming 251 that the former represents mainly CD8+ T cells and the latter represents CD4+ and CD8+ T 252 cells³¹, the result is consistent with the preferential induction of MHC-I-mediated CD8+ T cells in mouse studies²⁷. Furthermore, the priming effect of EXG-5003 was also consistent with the 253 priming effect shown in mouse studies²⁷. These results suggest that giving EXG-5003 as a 254 255 primer vaccine provides immunological benefits to subsequent booster synthetic mRNA 256 vaccines. As we showed in our mouse model, EXG-5003 induces the same immune 257 enhancement effects even when used as a booster vaccine. Therefore, it is conceivable that a 258 booster dose of EXG-5003 may confer immunologic benefits to people who have already 259 received licensed mRNA vaccines. For such purposes, another vaccine, EXG-5008 — the same 260 c-srRNA platform encoding for both RBD and nucleoproteins derived from SARS-CoV-2 and MERS-CoV²⁷, may be more suitable because it also has the benefit of more conserved 261 262 nucleoproteins as antigens and intent to be a so-called pan-coronavirus vaccine.

263 One potential advantage of using the combination of c-srRNA vaccine and synthetic mRNA 264 vaccine as heterologous prime-boost vaccines is that both are RNAs; thus, the advantages of 265 RNA vaccines, such as rapid development and simple manufacturing, apply to both. 266 Furthermore, the c-srRNA vaccine does not use LNPs or nucleoside modifications, which are 267 additional attractive features. 268 We acknowledge the limitations of our study. As a first-in-human trial of a novel c-srRNA 269 vaccine platform, the number of participants was designed to be small. Furthermore, participants 270 were allowed to take subsequent booster vaccines at their own will, resulting in even smaller 271 numbers of participants in each subgroup of heterologous prime-boost vaccinations. Because of 272 these small numbers, only the trends, without statistical inferences, were obtained. 273 In summary, we conducted a double-blind, placebo-controlled phase I/II trial to evaluate the 274 safety, tolerability, and immunogenicity of EXG-5003, a two-dose, controllable self-replicating RNA vaccine against SARS-CoV-2. No safety concerns were observed with EXG-5003 275 276 administration. SARS-CoV-2 RBD antibody titers and neutralizing antibody titers were not 277 elevated in either cohort, but elicitation of antigen-specific cellular immunity was observed in the 278 EXG-5003 recipients in Cohort 2. Additionally, those who received an approved mRNA vaccine 279 after receiving EXG-5003 showed higher cellular responses compared to equivalently vaccinated 280 participants in the placebo group, suggesting a priming effect towards the cellular immunity of approved SARS-CoV-2 mRNA vaccines, and the potential applications of c-srRNA based 281 282 vaccines against pathogens that depend on the cellular immunity protection. 283

Materials and Methods 284

285 EXG-5003 vaccine

286 The EXG-5003 vaccine was developed by Elixirgen Therapeutics, Inc. Its design and preclinical studies are described in the previous paper ²⁷. In brief, this RNA vaccine platform is based on a 287 288 self-replicating RNA (srRNA), also called self-amplifying RNA (saRNA or SAM), derived from 289 the Venezuelan Equine Encephalitis virus. This RNA vaccine platform contains temperature-290 sensitive mutations, which makes it function at around 33°C (skin temperature) but not at around 291 37°C (core body temperature). Thus, it is called controllable self-replicating RNA (c-srRNA). 292 The vaccine encodes the RBD of SARS-CoV-2 spike protein as an antigen. The EXG-5003 is 293 intradermally delivered as naked RNA, i.e., without lipid nanoparticles. The EXG-5003 c-srRNA 294 was diluted by Lactated Ringer's solution at the clinical site and adjusted to the desired concentration. 295

296 Trial design and participants

297 This was a single-center, phase 1/2, randomized, double-blinded, placebo-controlled trial

conducted to evaluate the safety, tolerability, and immunogenicity of EXG-5003 in adults. The

299 protocol, amendments, and overall oversight were approved by the Institutional Review Board

300 for the Fujita Health University Hospitals (F-D-18) (jRCT2041210013, NCT04863131). The

301 study was conducted in accordance with the Declaration of Helsinki.

302 The participants provided written informed consent before enrollment and randomization.

303 Healthy adults aged 20 to 55 years who had a negative PCR test for SARS-CoV-2 and a negative

304 anti-SARS-CoV-2 spike protein antibody were eligible. Key exclusion criteria included previous

305 receipt of approved SARS-CoV-2 vaccine, symptoms consistent with COVID-19, uncontrolled

- 306 cardiovascular, hematologic, respiratory, gastrointestinal, renal, and neuropsychiatric diseases,
- 307 diabetes, autoimmune diseases, history of hepatitis B, hepatitis C, HIV infection, anaphylaxis or

seizure, previous receipt of any SARS-CoV-2 vaccine, and ongoing pregnancy. Women of
childbearing age were required to document a negative pregnancy test.

310 Study procedures

311 The study enrolled two sequential cohorts, each consisting of 20 participants. Cohort 1

312 participants received 5 µg of EXG-5003 or placebo, whereas Cohort 2 participants received 25

313 µg of EXG-5003 or placebo. Participants were randomized in a 4:1 ratio to receive two 0.1 mL

314 intradermal injections of either EXG-5003 or placebo (Lactated Ringer's solution) to the

posterior upper arm region, 28 days apart on Day 1 and Day 29 of randomization. Allocation of

316 participants to the study arms were performed via a web-based interactive system by unblinded

317 allocation staff, followed by preparation of EXG-5003 or placebo solution by unblinded

318 pharmacists. The unblinded allocation staff and pharmacists who managed the study vaccine

319 preparation had no role in participant assessment. The participants were followed for 52 weeks.

320 The participants were allowed to receive SARS-CoV-2 vaccines that were approved in Japan

321 (BNT162b2, mRNA-1273, ChAdOx1, NVX-CoV2373) after Day 57 during the follow-up

322 period. In retrospect, most participants of this study received either BNT162b2 or mRNA-1273.

323 For humoral immunity comparison, the following sera were used: one WHO standard serum;

324 four convalescent individuals (serum was collected from COVID-19 patients hospitalized at

325 Fujita Health University Hospital at 20, 21, 21, and 22 days after the onset of symptoms,

326 respectively).

327 For cellular immunity comparison, blood samples were used from: three convalescent

328 individuals (blood was collected from COVID-19 patients hospitalized at Fujita Health

329 University Hospital at 20, 21, and 22 days after the onset of symptoms, respectively [patients are

the same convalescent individuals described above]); four individuals (unrelated to this clinical

- trial) before receiving a 1st dose [BNT162b2 (pre)]; three individuals two weeks after receiving
- the BNT162b2 mRNA vaccine [BNT162b2 (1 dose)]; and three individuals two weeks after
- receiving the 2nd dose [BNT162b2 (2 doses)].
- 334 Humoral immunity assays

335 Anti-RBD antibody

336 Antibody titers against SARS-CoV-2, including any antibodies that bind to the RBD, were 337 measured by electrochemiluminescent (ECL) technology. The ECL is an immunoassay based on the excitation of a ruthenium sulfo-tagged antibody by an electrical current. Biotinylated RBD of 338 339 the spike protein from SARS-CoV-2 (2019-nCoV) was captured onto an MSD Gold Streptavidin 340 coated plate (ECL capable) for coating. This recombinant protein consisted of 234 amino acids 341 corresponding to the RBD and had a predicted molecular mass of 28.7 kDa. A blocker solution 342 was added to the wells and subsequently washed. The antibodies against the SARS-CoV-2 spike 343 protein in the samples were captured onto the coated plate. After thorough washing of the wells 344 to remove the unbound antibodies, sulfo-tagged anti-human IgG-FC was added to the wells to 345 form a complex with the antibodies against the RBD. The excess unbound conjugate was then 346 removed by further washing. The reaction was then developed by adding MSD read buffer, and 347 the assay plate was read using an MSD ECL plate reader. The electrochemiluminescence signal 348 generated was relative to the amount of antibodies against the RBD present in the samples tested.

349 Cell-free SARS-CoV-2 neutralization assay

350 Neutralizing antibody titers against the RBD of SARS-CoV-2 were measured by AlphaLISA

351 technology. The AlphaLISA is an amplified luminescent proximity homogenous immunoassay

based on the proximity of two types of beads: acceptor and donor beads. Briefly, all samples

353 were initially diluted in assay diluent, diluted in MRD diluent, and transferred to an assay plate.

They were then incubated with a mixture of acceptor beads (streptavidin-coated) and 354 355 recombinant spike-RBD protein (biotinylated). During this step, the neutralizing antibodies 356 bound to the spike-RBD protein. Lastly, a mixture of donor beads (anti-FLAG coated) and 357 angiotensin-converting enzyme 2 (ACE2) protein (FLAG) were added to the reaction, by which 358 non-neutralized spike-RBD protein would bind to the ACE2 receptor, bringing closer both 359 acceptor and donor beads. Upon laser excitation, a photosensitizer present in the donor beads 360 converted ambient oxygen to a more excited singlet state. The singlet oxygen channeled into the 361 acceptor beads and reacted with a thioxene derivate in the acceptor beads, generating 362 chemiluminescence at 370 nm that further activated a fluorophore (europium) embedded in the 363 acceptor beads. The fluorophore subsequently emitted light at 615 nm, which was measured by 364 the Envision reader. The amount of light generated in counts (cps) was inversely proportional to 365 the amount of neutralizing antibodies against the RBD of the SARS-CoV-2 spike protein. 366 SARS-CoV-2 spike pseudotyped lentivirus assay 367 Neutralizing antibody titers against the RBD of SARS-CoV-2 were also measured by quasi-368 quantification of the antibody response in a titer approach. This cell-based assay using 293T-369 hsACE2 cells is based on the principle that binding between the SARS-CoV-2 spike protein and 370 the cellular receptor ACE2 protein is necessary for cellular infection. In the presence of 371 neutralizing antibodies, the spike protein function is affected, and therefore, the binding between 372 the spike and ACE2 proteins is negatively affected. This assay uses luciferase reporter virus 373 particles (RVPs).

374 Samples were initially diluted in cell culture media and transferred to a 96-well plate. A known

375 quantity of RVPs (or pseudovirus) was added and incubated to allow antibody binding. A set

376 quantity of 293T-ACE2 cells was added, and plates were incubated for 48 hours. After the

377 incubation period, a luciferase substrate was added to each well, and relative light unit (RLU)

378 values were read using luminescence settings. The amount of RLUs was inversely proportional

to the amount of neutralizing antibodies against the SARS-CoV-2 spike protein.

380 The inhibitory rates were calculated based on RLU values and used for assessing antibody and

381 serum neutralization activities. The endpoint titers were calculated by serial dilutions of the

382 samples.

383 Cellular immunity assays

384 FluoroSpot assay

385 This FluoroSpot (FS) assay was conducted to detect and quantify interferon gamma (IFN- γ) and

386 interleukin 4 (IL-4) secretion by antigen-stimulated human PBMCs. PBMCs were isolated from

387 three groups, including participants of this trial, convalescent patients who were hospitalized and

388 recovering from COVID-19, and participants of a separate study that enrolled individuals

receiving the BNT162b2 mRNA vaccine. SARS-CoV-2 peptide pools (9-mers and 15-mers) and

390 controls (Phytohemagglutinin, Dimethyl sulfoxide, and CPI [protein antigens of CMV,

391 Parainfluenza and Influenza viruses]) were used as stimulants.

392 Peptide pools used to stimulate PBMC are described in a previous paper ²⁷. In brief, the 15-mer

393 peptide pool is a pool of 53 peptides derived from a peptide scan (15-mers with 11 amino acid

394 overlap) through the RBD of SARS-CoV-2 (an original Wuhan strain) [JPT Peptides: PepMix

395 SARS-CoV-2 (S-RBD) PM-WCPV-S-RBD-2]. The 9-mer peptide pool is a pool of 215 peptides

- derived from a peptide scan (9-mers with 8 amino acid overlaps) through the RBD of SARS-
- 397 CoV-2 (an original Wuhan strain). The 9-mer peptide pool was custom-made by JPT Peptides. It
- is known that the 15-mer peptide pool induces both CD8+ T cell response and CD4+ T cell

399	response reliably, whereas the 9-mer peptide pool induces primarily CD8+ T cell response;
400	however, the CD4+ T cell response is also induced less reliably ^{31} .

- 401 FluoroSpot assay plates were washed with PBS and blocked with CTL media for \geq 30 mins at
- 402 37°C. Post-thaw PBMCs were seeded at $4x10^{5}$ cells per well (100 µL) and stimulated in
- triplicate with one of the following five different stimulants: 1 µg/mL of 9-mer SARS-CoV-2 or
- 404 15-mer SARS-CoV-2 peptide pools, 5 μg/mL CPI, 3 μg/mL PHA, or DMSO (negative control).
- The final combined volume of cells and stimulant was 200 µL per well. Following 48 hours of
- 406 incubation, plates were washed and incubated with Fluorescein isothiocyanate (FITC)-labeled
- 407 anti-IFN- γ or biotinylated anti-IL-4 detection antibodies for 2 hours at room temperature in the
- 408 dark. Plates were then washed and incubated for 1 hour at room temperature in the dark with
- 409 either anti-FITC Alexa Fluor 488 tertiary antibody for detecting IFN-γ or streptavidin CTL Red
- 410 for detecting IL-4. Plates were finally washed with water and placed in the dark to dry overnight.
- 411 Within 24-36 hours after development, plates were scanned using the CTL. The numbers of spot-
- 412 forming cells (SFCs) were normalized to spots per million cells to yield spot-forming units
- 413 (SFUs).

414 Safety assessment

415 Local and systemic adverse events, as defined in the FDA guidance for preventive vaccine

- 416 clinical trials, were solicited at each follow-up visit (Days 1, 8, 15, 29, 36, 43, 57, 92, 183, 365).
- 417 Laboratory values including complete blood count, basic metabolic panel, liver function tests,
- 418 and urinalysis were assessed on select follow-up visits (Days 1, 8, 29, 36, 57).

419 Statistical analysis

- 420 Data were analyzed using R (version 4.1.0) and GraphPad Prism (version 10.0.2). Sample size
- 421 was determined in advance primarily for feasibility considerations rather than through statistical

422	inferential testing. Due to a small sample size, only descriptive statistics were used and presented
423	in this paper.

424

425 Supplementary materials

- 426 The following supporting information can be downloaded at: www.mdpi.com/xxx/s1, Table S1:
- 427 Antibody titers; Table S2: Antibody titers of external controls; Table S3: Neutralizing Antibody
- 428 titers (Cell-free assays); Table S4: Neutralizing Antibody titers (Pseudovirus assays); Table S5:
- 429 Fluorospot assay results at 1-year post-EXG-5003 vaccination; Table S6: Fluorospot assay
- 430 results for external controls.

431

432 Author contributions

- 433 TK, MT, HF, MaK, YD conducted the clinical trial at Fujita Health University. MiK coordinated
- 434 regulatory activities. MSHK, TA, MA, MB, HY, PR, EL, JK, HY, ACK, NPW, AA were involved in
- 435 EXG-5003 vaccine development. HY conducted data management. IT, ST, AS conducted planned
- 436 statistical analyses. MSHK and YD conducted post-hoc statistical analyses and drafted the

437 manuscript.

438

439 Funding

- 440 This clinical trial was entirely supported by AMED under Grant Number JP21nf0101631. Elixirgen
- 441 Therapeutics provided the EXG-5003 vaccine.

442

443 Institutional review board statement

444	The protocol, amendments, and overall oversight were approved by the Central Institutional Review		
445	Board for the Fujita Health University Hospitals (F-D-18) (jRCT2041210013, NCT04863131). The		
446	study was conducted in accordance with the Declaration of Helsinki.		
447			
448	Inform	ned consent statement	
449	Inform	ned consent was obtained from all participants involved in the study.	
450			
451	Data a	availability statement	
452	The da	ata presented in this study can be found in Figures, Tables, and Supplemental Tables.	
453			
454	Ackno	owledgments	
455	We thank Allie Amick, Ph.D. for editing the manuscript.		
456			
457	Confli	icts of interest	
458	MiK is a paid consultant to Elixirgen Therapeutics, Inc. TA, HY, MA, MB, PR, ACK, MSHK are		
459	employees of Elixirgen Therapeutics, Inc. EL and JK were former employees of Elixirgen		
460	Therapeutics, Inc. AA and NW are employees of the National Institute on Aging, National Institutes		
461	of Health, and declare no competing interests. YD has served as a consultant for Moderna. TK, TM,		
462	TI, HY	, ST, AS, HF, MaK declare no competing interest.	
463			
464	Refer	ences	
465	1	WHO Coronavirus Dashboard (2023). https://covid19.who.int/	
466	2	Excler, J. L. et al. Factors, enablers and challenges for COVID-19 vaccine development.	
467		BMJ Glob Health 8 (2023). https://doi.org/10.1136/bmjgh-2023-011879	

- 468 3 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N
- 469 *Engl J Med* **384**, 403-416 (2021). <u>https://doi.org/10.1056/NEJMoa2035389</u>
- 470 4 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N
- 471 Engl J Med **383**, 2603-2615 (2020). <u>https://doi.org/10.1056/NEJMoa2034577</u>
- 472 5 Moss, P. The T cell immune response against SARS-CoV-2. *Nat Immunol* 23, 186-193
- 473 (2022). <u>https://doi.org/10.1038/s41590-021-01122-w</u>
- 474 6 Sette, A., Sidney, J. & Crotty, S. T Cell Responses to SARS-CoV-2. Annu Rev Immunol
- 475 **41**, 343-373 (2023). <u>https://doi.org/10.1146/annurev-immunol-101721-061120</u>
- 476 7 Wherry, E. J. & Barouch, D. H. T cell immunity to COVID-19 vaccines. *Science* 377,
- 477 821-822 (2022). <u>https://doi.org/10.1126/science.add2897</u>
- 478 8 Anderson, E. J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine
- 479 in Older Adults. *N Engl J Med* **383**, 2427-2438 (2020).
- 480 <u>https://doi.org/10.1056/NEJMoa2028436</u>
- 481 9 Nathan, A. *et al.* Structure-guided T cell vaccine design for SARS-CoV-2 variants and
- 482 sarbecoviruses. *Cell* **184**, 4401-4413 e4410 (2021).
- 483 <u>https://doi.org/10.1016/j.cell.2021.06.029</u>
- 484 10 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 Preliminary Report. N
- 485 Engl J Med **383**, 1920-1931 (2020). <u>https://doi.org/10.1056/NEJMoa2022483</u>
- 486 11 Munro, A. P. S. et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and
- 487 mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of
- 488 ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a
- 489 multicentre, blinded, phase 2, randomised trial. *Lancet Infect Dis* **22**, 1131-1141 (2022).
- 490 https://doi.org/10.1016/S1473-3099(22)00271-7

- 491 12 Ozbay Kurt, F. G. et al. Booster dose of mRNA vaccine augments waning T cell and
- 492 antibody responses against SARS-CoV-2. *Front Immunol* **13**, 1012526 (2022).
- 493 <u>https://doi.org/10.3389/fimmu.2022.1012526</u>
- 494 13 Hernandez, S. P. A. et al. Three doses of BNT162b2 COVID-19 mRNA vaccine establish
- 495 long-lasting CD8(+) T cell immunity in CLL and MDS patients. *Front Immunol* **13**,
- 496 1035344 (2022). https://doi.org/10.3389/fimmu.2022.1035344
- 497 14 Reinscheid, M. et al. COVID-19 mRNA booster vaccine induces transient CD8+ T
- 498 effector cell responses while conserving the memory pool for subsequent reactivation.
- 499 *Nat Commun* **13**, 4631 (2022). <u>https://doi.org/10.1038/s41467-022-32324-x</u>
- 500 15 Agrati, C. et al. Persistent Spike-specific T cell immunity despite antibody reduction after
- 501 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. *Sci Rep* **12**, 6687 (2022).
- 502 <u>https://doi.org/10.1038/s41598-022-07741-z</u>
- 503 16 Blakney, A. K., Ip, S. & Geall, A. J. An Update on Self-Amplifying mRNA Vaccine
- 504 Development. Vaccines (Basel) 9 (2021). <u>https://doi.org/10.3390/vaccines9020097</u>
- 505 17 McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine
- 506 candidate induces high neutralizing antibody titers in mice. *Nat Commun* **11**, 3523
- 507 (2020). <u>https://doi.org/10.1038/s41467-020-17409-9</u>
- 508 18 de Alwis, R. et al. A single dose of self-transcribing and replicating RNA-based SARS-
- 509 CoV-2 vaccine produces protective adaptive immunity in mice. *Mol Ther* **29**, 1970-1983
- 510 (2021). <u>https://doi.org/10.1016/j.ymthe.2021.04.001</u>
- 511 19 Erasmus, J. H. et al. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2
- 512 neutralizing antibody and T cell responses in mice and nonhuman primates. *Sci Transl*
- 513 *Med* **12** (2020). https://doi.org/10.1126/scitranslmed.abc9396

E 4 4	20	I an annia N/ A stal An alghering neglicen hand we asing a sympanic a stabilized
514	/11	Langereis IVI A $\rho_I \alpha_I$ An ainnavirus replicon-based vaccine expressing a stabilized
011	20	Euligereis, m. m. et al. mit alphavirus repriedit dubea vadente expressing a sudmizea

- 515 Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2
- 516 between cats. *NPJ Vaccines* **6**, 122 (2021). <u>https://doi.org/10.1038/s41541-021-00390-9</u>
- 517 21 Szurgot, I. *et al.* DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2
- 518 immune responses in mice. *Sci Rep* **11**, 3125 (2021). <u>https://doi.org/10.1038/s41598-021-</u>
- 519 <u>82498-5</u>
- 520 22 Rappaport, A. R. et al. Low-dose self-amplifying mRNA COVID-19 vaccine drives
- 521 strong protective immunity in non-human primates against SARS-CoV-2 infection. *Nat*
- 522 *Commun* **13**, 3289 (2022). <u>https://doi.org/10.1038/s41467-022-31005-z</u>
- 523 23 Komori, M. et al. saRNA vaccine expressing membrane-anchored RBD elicits broad and
- durable immunity against SARS-CoV-2 variants of concern. *Nat Commun* 14, 2810
- 525 (2023). <u>https://doi.org/10.1038/s41467-023-38457-x</u>
- 526 24 Akahata, W. et al. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA
- 527 vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study. *Cell*
- 528 *Rep Med* **4**, 101134 (2023). <u>https://doi.org/10.1016/j.xcrm.2023.101134</u>
- 529 25 Elliott, T. et al. Enhanced immune responses following heterologous vaccination with
- self-amplifying RNA and mRNA COVID-19 vaccines. *PLoS Pathog* **18**, e1010885
- 531 (2022). <u>https://doi.org/10.1371/journal.ppat.1010885</u>
- 532 26 Low, J. G. et al. A phase I/II randomized, double-blinded, placebo-controlled trial of a
- self-amplifying Covid-19 mRNA vaccine. *NPJ Vaccines* **7**, 161 (2022).
- 534 https://doi.org/10.1038/s41541-022-00590-x

- 535 27 Amano, T. et al. Controllable self-replicating RNA vaccine delivered intradermally
- elicits predominantly cellular immunity. *iScience* **26**, 106335 (2023).
- 537 <u>https://doi.org/10.1016/j.isci.2023.106335</u>
- 538 28 Dugan, H. L., Henry, C. & Wilson, P. C. Aging and influenza vaccine-induced immunity.
- 539 *Cell Immunol* **348**, 103998 (2020). <u>https://doi.org/10.1016/j.cellimm.2019.103998</u>
- 540 29 Hickling, J. K. et al. Intradermal delivery of vaccines: potential benefits and current
- 541 challenges. *Bull World Health Organ* **89**, 221-226 (2011).
- 542 <u>https://doi.org/10.2471/BLT.10.079426</u>
- 543 30 Pollock, K. M. et al. Safety and immunogenicity of a self-amplifying RNA vaccine
- against COVID-19: COVAC1, a phase I, dose-ranging trial. *EClinicalMedicine* 44,
- 545 101262 (2022). <u>https://doi.org/10.1016/j.eclinm.2021.101262</u>
- 546 31 Kiecker, F. et al. Analysis of antigen-specific T-cell responses with synthetic peptides--
- 547 what kind of peptide for which purpose? *Hum Immunol* **65**, 523-536 (2004).
- 548 <u>https://doi.org/10.1016/j.humimm.2004.02.017</u>
- 549
- 550

551 Table 1. Participants demographics.

552

	Cohort 1		Cohort 2	
	EXG-5003 5 μg (n=16)	Placebo (n=4)	EXG-5003 25 μg (n=16)	Placebo (n=4)
Race Asian	16 (100%)	4 (100%)	16 (100%)	4 (100%)
Gender Male Female	10 (62.5%) 6 (37.5%)	3 (75%) 1 (25%)	7 (43.8%) 9 (56.2%)	4 (100%) 0 (0%)
Age (year) Mean SD Median Min-Max	39.375 8.405 39.5 22 - 53	46.75 7.932 48.0 36 - 55	39.562 10.354 43.0 22 - 55	42.75 4.272 44.0 37 - 46
Weight (kg) Mean SD Median Min-Max	66.862 18.756 61.5 46.9 - 107.8	64.8 4.721 65.85 58.2 - 69.3	63.094 12.837 63.05 47.5 - 84.7	74.625 10.633 72.9 65 - 87.7
Height (cm) Mean SD Median Min-Max	169.200 8.791 170.550 154.2 - 183.1	169.375 6.874 172.55 159.1 - 173.3	164.162 8.804 164.550 152 - 180	169.175 5.142 170.35 162 - 174
BMI (kg/m ²) Mean SD Median Min-Max	23.265 6.072 21.484 17.849 - 39.789	22.575 0.534 22.593 22.039 - 23.075	23.301 3.680 22.637 16.553 - 29.938	26.173 4.374 26.269 22.13 - 30.026

553 Note. SD, standard deviation; Min, minimum; Max, maximum; BMI, body mass index.

554 FIGURE LEGENDS

555

- **Figure 1.** A flow chart showing enrollment and randomization of participants. Cohort 1 (5 μg
- 557 group) was dosed first. After the second dose, the safety was monitored for two weeks. Then,
- 558 Cohort 2 (25 μ g group) was dosed.

559

Figure 2. Safety of EXG-5003. (A) Frequency of local adverse events within 7 days of

561 vaccination and a photo example of redness at the intradermal injection site. (B) Frequency of

562 systemic adverse events within 7 days of vaccination.

563

564 Figure 3. Humoral immune responses against the RBD of SARS-CoV-2. Geometric means of

antibody titers. (A) Geometric means of anti-RBD antibody titer. (B) Geometric means of

566 neutralization antibody titer by cell-free SARS-CoV-2 neutralization assay. (C) Geometric

567 means of neutralization antibody titer by the SARS-CoV-2 spike pseudo-typed lentivirus assay.

568 Red color indicates participants who received at least one dose of approved mRNA vaccine

569 (BNT162b2 or mRNA-1273). FAS, the full analysis data set.

570



units (SFU) per 10⁶ PBMCs stimulated by 15-mer RBD peptide library. (B) IFN- γ SFU per

- 573 10⁶ PBMCs stimulated by 9-mer RBD peptide library. (C) IL-4 SFU per 10⁶ PBMCs
- stimulated by 15-mer RBD peptide library. (D) IL-4 SFU per 10⁶ PBMCs stimulated by 9-mer

575 RBD peptide library. Red color indicates data points after receiving at least one dose of approved

576 mRNA vaccine (BNT162b2 or mRNA-1273). External controls (for 15-mer RBD peptide

577	library): Convalescent (n=3, blood was collected 20, 21, 22 days after the onset of symptoms,				
578	respectively), BNT162b2 vaccine (pre) (n=4, before receiving 1st dose of BNT162b2),				
579	BNT162b2 (1 dose) (n=3, two weeks after receiving the 1st dose of BNT162b2), BNT162b2				
580	vaccine (2 doses) (n=3, two weeks after receiving the 2nd dose of BNT162b2). External controls				
581	(for 9-mer RBD peptide library): Convalescent (n=1, blood was collected 20 days after the onset				
582	of symptoms, respectively), BNT162b2 vaccine (pre) (n=1, before receiving 1st dose of				
583	BNT162b2), BNT162b2 vaccine (2 doses) (n=1, two weeks after receiving the 2nd dose of				
584	BNT162b2).				
585					
586	Figure 5. Cohort 2 cellular immune response data replotted from Figure 4 by log-scale. IFN- γ				
587	spot-forming units (SFU) per 10 ⁶ PBMCs stimulated by 15-mer peptide library. Placebo (n=4)				
588	in blue dots (left). EXG-5003 (25 μ g, n=16) in red dots (middle). External controls:				
589	Convalescent (n=3, blood was collected 20, 21, 22 days after the onset of symptoms,				
590	respectively), BNT162b2 vaccine (pre) (n=4, before receiving 1st dose of BNT162b2),				
591	BNT162b2 vaccine (dose 1) (n=3, two weeks after receiving the 1st dose of BNT162b2),				
592	BNT162b2 vaccine (2 doses) (n=3, two weeks after receiving the 2nd dose of BNT162b2).				
593	External controls (for 9mer peptide library): Convalescent (n=1, blood was collected 20 days				
594	after the onset of symptoms, respectively), BNT162b2 vaccine (pre) (n=1, before receiving 1st				
595	dose of BNT162b2), BNT162b2 vaccine (2 doses) (n=1, two weeks after receiving the 2nd dose				
596	of BNT162b2).				
597					

Figure 6. Long-term humoral immunity assessed by serum collected at 3 months, 6 months, and
1-year post-dosing with placebo (PBO), EXG-5003 (5 μg), or EXG-5003 (25 μg). Participants

600	who received the approved mRNA vaccines (BNT162b2 or mRNA-1273) more than 10 days
601	before the serum collection are shown. (A) Anti-RBD antibody titer. (B) Neutralization antibody
602	titer by cell-free SARS-CoV-2 neutralization assay. (C) Neutralization antibody titer by the
603	SARS-CoV-2 spike pseudo-typed lentivirus assay. * indicates individuals who became positive
604	for antibodies against SARS-CoV-2 nucleoprotein, i.e., infected during 1-year follow-up period.
605	
606	Figure 7. Long-term cellular immunity assessed by PBMCs collected at 1-year post-dosing with
607	placebo (PBO), EXG-5003 (5 µg), or EXG-5003 (25 µg).
608	(A) IFN- γ spot-forming units (SFU) per 10 ⁶ PBMCs stimulated by 15-mer RBD peptide
609	library. Participants were subdivided into three groups based on the timing of receiving the
610	approved mRNA vaccines (BNT162b2 or mRNA-1273): No booster (days after receiving PBO
611	[337 days], EXG-5003 5 µg [337 days], or EXG-5003 25 µg [337 days]), 2x booster (days after
612	receiving the 2 nd dose of approved vaccines: PBO [205, 262 days], EXG-5003 5 µg [70, 190,
613	212, 253 days]; EXG-5003 25 µg [3, 205, 253, 270, 272, 283 days]), 3x booster (days after
614	receiving the 3^{rd} dose of approved vaccines: PBO [46, 59, 63, 78 days]; EXG-5003 5 µg [13, 20,
615	21, 40 days]; EXG-5003 25 µg [20, 26, 61, 63, 68 days]). External controls (reproduced from
616	Figure 5 for comparison): Convalescent (n=3, blood was collected 20, 21, 22 days after the onset
617	of symptoms, respectively), BNT162b2 (pre) (n=4, before receiving 1st dose of BNT162b2),
618	BNT162b2 (1 dose) (n=3, two weeks after receiving the 1st dose of BNT162b2), BNT162b2 (2
619	doses) (n=3, two weeks after receiving the 2nd dose of BNT162b2). * indicates individuals who
620	became positive for antibodies against SARS-CoV-2 nucleoprotein, i.e., infected during 1-year
621	follow-up period.

- 623 (B) IFN- γ SFU per 10⁶ PBMCs stimulated by 9-mer RBD peptide library. Participants were
- 624 subdivided into three groups based on the timing of receiving the approved mRNA vaccines
- 625 (BNT162b2 or mRNA-1273): No booster (days after receiving EXG-5003 5 μg [337 days], or
- 626 EXG-5003 25 μg [337 days]), 2x booster (days after receiving the 2nd dose of approved vaccines:
- 627 PBO [205, 262 days], EXG-5003 5 μg [70, 190, 212, 253 days]; EXG-5003 25 μg [3, 205, 270
- 628 days]), 3x booster (days after receiving the 3rd dose of approved vaccines: PBO [78 days]; EXG-
- 629 5003 5 μg [13, 21, 40 days]; EXG-5003 25 μg [20, 25, 63 days]). External controls (for 9mer
- 630 peptide library): Convalescent (n=1, blood was collected 20 days after the onset of symptoms,
- 631 respectively), BNT162b2 (pre) (n=1, before receiving 1st dose of BNT162b2), BNT162b2 (2
- doses) (n=1, two weeks after receiving the 2nd dose of BNT162b2). * indicates individuals who
- 633 became positive for antibodies against SARS-CoV-2 nucleoprotein, i.e., infected during 1-year
- 634 follow-up period.









Figure 4









Figure 6



Figure 7